TSE:4568Pharmaceuticals
Is Daiichi Sankyo (TSE:4568) Turning ENHERTU’s China Approval Into a Durable Oncology Advantage?
Daiichi Sankyo recently gained approval in China for ENHERTU as the first HER2-directed antibody-drug conjugate for second-line treatment of HER2 positive metastatic gastric cancer, while also advancing its ADC pipeline and transitioning leadership at its Translational Research Center Europe.
This approval taps into China’s large gastric cancer burden and underscores the central role of Daiichi Sankyo’s DXd ADC platform in its oncology franchise.
We’ll now examine how ENHERTU’s new gastric...